Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. MT203 is being developed in collaboration with Nycomed, and the first clinical trial with MT203 is expected to be initiated in the first half of 2009. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements


'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The new report by ... applications, techniques, end users and Geography) Global Size, ... - 2020," indicates that the global DNA diagnostics ... a CAGR of 9.8% from 2014 to 2020. ... effectiveness over alternative diagnostic techniques are factors which ...
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... N.J., Oct. 17 Ten abstracts providing new,analyses of ... for,MIRCERA(R) will be presented at the upcoming 40th Annual ... Francisco on November 2 - 5,2007. Among the ... PROTOS, STRIATA and RUBRA, and correction studies,including ARCTOS and ...
... MOINES, Iowa, Oct. 16 Protocol Driven ... announced a partnership,with Hallmark Insights to provide ... users of the ConXus health improvement platform. ... fulfillment services,for reward points earned by participants ...
Cached Medicine Technology:New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting 2New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting 3New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting 4PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal delivery ... meal plan. Originating from The Fresh Diet’s commitment to ... designed to satisfy customers seeking a convenient, worry-free option ... to the growing demand by customers for non-meat menu ... with 14% of Americans identifying vegetarian meals as ‘more ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 As ... Cooper City, Fla., understands that there’s a direct connection ... the knees, hips and back. "Since conventional shoe inserts ... design a solution of my own," he said. , ... Orthotic provides better support for the foot in order ...
(Date:8/29/2014)... 29, 2014 Williams Rejuva Center is ... their Latham aesthetic office. Dr. Edwin Williams, known ... the first surgeons in the area to employ the ... technique is faster and safer than similar products available ... a noninvasive procedure , designed to dramatically improve ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... Dennis Thompson HealthDay Reporter ... research performed during the early days of the Ebola outbreak ... the virus mutates and spreads. Researchers report in the ... have now determined the following: The Ebola strains ... dating back to the very first recorded outbreak of Ebola ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Williams Revjuva Center Brings Micro-Needling to Latham 2Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3
... have observed a high resolution camera which detects tumours ... been comparing mammography with a technique called scintimammography, which ... is good at distinguishing between malignant and benign tumours, ... limitation of this kind of camera is that it ...
... to Japanese researchers, genetic abnormalities bound with marijuana-activated ... a lead researcher, of the Okayama University, observed ... use can result in schizophrenia or a considerablelly ... of the greatest mental health challenges in the ...
... looked at data for treatment of sub-arachnoid haemorrhage (SAH) in ... by bleeding into the brain do best in hospitals dealing ... within the blood supply surrounding the brain's exterior. It can ... nearly 10,000 patients admitted to 300 emergency departments was scanned, ...
... of antidepressant, called venlafaxine,assists patients with social anxiety disorder. ... and dread in relation to meeting and talking with ... situations a huge problem. Many of those with SAD ... condition can be hard to treat. ,Researchers ...
... ,According to a recent study, spending time in an Indian ... in a new study, India, looked at how traditional healing ... Muthuswamy in South India has long been a healing centre ... during a short period in 1000 were enrolled in the ...
... observed that, people suffering from heat diseases are better off ... for a few it might prove too much.People who are ... safe to enjoy a game of golf.// Researchers at the ... male golfers, aged between 50 and 75, half of whom ...
Cached Medicine News:Health News:Gene glitches connecting pot with Schizophrenia 2
4.625 inches, curved blade 4 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
In reversible handle for removing foreign bodies....
Medicine Products: